Serum tumour markers in gynaecological cancers

被引：60

作者：

Aggarwal, Pakhee ^{[1
]}

Kehoe, Sean ^{[1
]}

机构：

[1] Churchill Hosp, Oxford Gynaecol Canc Ctr, Dept Gynaecol Oncol, Oxford OX3 7LJ, England

来源：

MATURITAS | 2010年 / 67卷 / 01期

关键词：

Serum tumour markers; Ovarian cancer; Endometrial cancer; CA125; Cervical cancer; GERM-CELL TUMORS; OVARIAN-CANCER; ENDOMETRIAL CANCER; CERVICAL-CANCER; ALPHA-FETOPROTEIN; CARCINOMA ANTIGEN; PROGNOSTIC FACTOR; CA125; EXPRESSION; FOLLOW-UP; INHIBIN-B;

D O I：

10.1016/j.maturitas.2010.04.017

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Serum tumour markers have had a role in screening, diagnosis and monitoring of some gynaecological cancers. Women with suspected ovarian malignancies have as routine a CA125 serum test, and in conjunction with scans, the risk of malignancy can be calculated. Equally, this CA125, if elevated pre-operatively can be used to predict chemotherapeutic responses, and even disease relapse prior to any symptoms or clinical findings. Other useful markers in ovarian cancer are beta HCG and AFP produced by germ cell tumours. beta HCG is also of extreme importance in both the diagnosis and management of choriocarcinomas. The level of beta HCG determines the need, and with other indicators, the type of chemotherapeutic intervention. Other serum markers are known in cervical cancer, and possibly endometrial and vulval cancer-but their clinical utility is very limited. Novel markers may help in managing patients, and in the future permit screening for certain diseases. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：46 / 53

页数：8

共 65 条

[31] Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus [J].

Moore, Richard G. ;

Brown, Amy K. ;

Miller, M. Craig ;

Badgwell, Donna ;

Lu, Zhen ;

Allard, W. Jeffrey ;

Granai, C. O. ;

Bast, Robert C., Jr. ;

Lu, Karen .

GYNECOLOGIC ONCOLOGY, 2008, 110 (02) :196-201

[32] A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass [J].

Moore, Richard G. ;

McMeekin, D. Scott ;

Brown, Amy K. ;

DiSilvestro, Paul ;

Miller, M. Craig ;

Allard, W. Jeffrey ;

Gajewski, Walter ;

Kurman, Robert ;

Bast, Robert C., Jr. ;

Skates, Steven J. .

GYNECOLOGIC ONCOLOGY, 2009, 112 (01) :40-46

[33] Malignant ovarian germ cell tumors: Identification of novel prognostic markers and long-term outcome after multimodality treatment [J].

Murugaesu, Nirupa ;

Schmid, Peter ;

Dancey, Gairin ;

Agarwal, Roshan ;

Holden, Lydia ;

McNeish, Iain ;

Savage, Philip M. ;

Newlands, Edward S. ;

Rustin, Gordon J. S. ;

Seckl, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (30) :4862-4866

[34] Use of proteomic patterns in serum to identify ovarian cancer [J].

Petricoin, EF ;

Ardekani, AM ;

Hitt, BA ;

Levine, PJ ;

Fusaro, VA ;

Steinberg, SM ;

Mills, GB ;

Simone, C ;

Fishman, DA ;

Kohn, EC ;

Liotta, LA .

LANCET, 2002, 359 (9306) :572-577

[35]

Powell JL, 2005, J REPROD MED, V50, P585

[36]

PUTHUCODEEASWAR.N, 2005, J OBSTET GYNAECOL, V25, P486

[37]

Ray-Coquard I, 2004, ORPHANET ENCY

[38] Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: Comparative study with serum alpha-inhibin and estradiol [J].

Rey, RA ;

Lhomme, C ;

Marcillac, I ;

Lahlou, N ;

Duvillard, P ;

Josso, N ;

Bidart, JM .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 174 (03) :958-965

[39] Inhibin/activin and ovarian cancer [J].

Robertson, DM ;

Burger, HG ;

Fuller, PJ .

[40] Characterization of inhibin forms and their measurement by an inhibin α-subunit ELISA in serum from postmenopausal women with ovarian cancer [J].

Robertson, DM ;

Stephenson, T ;

Pruysers, E ;

McCloud, P ;

Tsigos, A ;

Groome, N ;

Mamers, P ;

Burger, HG .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :816-824

← 1 2 3 4 5 6 7 →